Myoinositol as a Biomarker in Recurrent Glioblastoma Treated with Bevacizumab: A 1H-Magnetic Resonance Spectroscopy Study

@inproceedings{Steidl2016MyoinositolAA,
  title={Myoinositol as a Biomarker in Recurrent Glioblastoma Treated with Bevacizumab: A 1H-Magnetic Resonance Spectroscopy Study},
  author={Eike Steidl and Ulrich Pilatus and Elke Hattingen and Joachim Peter Steinbach and Friedhelm E. Zanella and Michael W Ronellenfitsch and Oliver Baehr},
  booktitle={PloS one},
  year={2016}
}
BACKGROUND Antiangiogenic treatment of glioblastomas with Bevacizumab lacks predictive markers. Myoinositol (MI) is an organic osmolyte, with intracellular concentration changes depending on the extracellular osmolality. Since Bevacizumab markedly reduces tumor edema and influences the tumor microenvironment, we investigated whether the MI concentration in the tumor changes during therapy. METHODS We used 1H-magnetic resonance spectroscopy to measure the MI concentrations in the tumor and… CONTINUE READING